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jie Zhang 
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John]. Wheeler 
Tennessee Technological University 
Abstract: The prevalence of autism has increased approximately four times in children in nearly lme decade 
(Califqmia Heallh and Human Services Agency, 2003). It has been reported that explanations such as 
immigration, shifts in the interpretation of diagnostic criteria, imprU!!ed identification, or diagnostic accuracies 
cannot explain the obseroed increase (Geier & Geier, 2005). One potential cause that has alarmed many has 
been the presence of thimersol, the mercury-based preseroatiue found among immunizations. Although many 
refute this, concern has been leveled by many families and professionals concerning the potential impact of 
mercury poisoning as a causal factor. Researchers have proposed thaJ autism may be in part caused by mercury, 
because there was cumulative mercury exposure through dental amalgam, fish consumption, environment 
pollution, and additionally, through increased thimerosal-containing vaccines for both mothers and newborns 
(Mutter, Naumann, Schneider, Walach, & Haley, 2005). The purpose of this study is to review the 
infarmation from studies concerning the relationship between mercury exposure and autism. 
ll has been estimated that prevalence of au­
tism has increased approximately four times 
in childhood autism in about one decade, 
from 1 in 1,333 children (7.5 per 10,000 
children) among child1·en born in the mid­
l980s to 1 in 323 children (31.2 per 10,000 
children) among children born in the late-
1990s (California Health and Human Services 
Agency, 2003). In 2004, the Department of 
Health and Human Services and the Ameri­
can Academy of Pediatrics issued an Autism 
ALARM claiming that presently I in 166 chil­
dren (60 per 10,000 children) has autism. In 
California, the autism rate increased by 634% 
be£Ween 1987 and 2002 (California Health 
and Human Services Agency). Once a rare 
disorder, autism has now been found to be 
more prevalent than childhood cancer, diabe­
tes and Down Syndrome (California Health 
and Human Services Agency). It has been re­
ported that explanations such as immigration, 
shifts in the interpretation of diagnostic crite­
ria, improved identification, or diagnostic ac­
curacies cannot explain the observed increase 
(Geier & Geier, 2005). Researchers have pro-
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posed that autism may be in part caused by 
mercury, because there was cumulative mer­
cury exposure through fish and industrial 
sources, amalgam and additionally, through 
increased thimerosal-containing vaccines for 
both mothers and newborns (Mutter, Nau­
mann, Schneider, et a!., 2005). 
Similarities Between Autism and 
Mercury Poisoning 
The harmful effects of mercury include im­
paired motor planning, decreased facial rec­
ognition, blurred vision and constricted visual 
fields, insomnia, irritability, tantrums, excit­
ability, social withdrawal, anxiety, difficulty 
verbalizing, altered taste, impaired short-term 
memory, slowed reaction time and difficulty 
with concentration (Jepson, 2004). Bernard, a 
parent of a child with autism, and several 
other investigators compared signs and symp­
toms of mercury poisoning with those of au­
tism (Bernard, Enayati, et al., 2001). Distinct 
similarities were found between autism and 
mercury exposure in their effects upon im­
mune, sensory, neurological, motor, and be­
havioral dysfunctions, and these similarities 
extend to neuroanatomy, neurotransmitters, 
and biochemistry (Geier & Geier, 2005). 
Thus, Bernard, Enayati, et al. suggest that the 
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regressive form of autism represents a form of 
mercury poisoning (Bernard, Enayati, et al.). 
Historically, there were such illnesses caused 
by environmental exposure to mercury as 
Acrodynia or Pink's disease and Minamata's 
disease. Like autism, these diseases also pre­
sented with large range of variability and sus­
ceptibility among indi.,iduals in the popula­
tion and were eradicated when the source of 
the exposure was eliminated Qepson, 2004). 
In the early 20th century, Acrodynia (Pink's 
Disease) affected up to I of 500 infants in 
some industrial countries. Acrodynia disap­
peared after a frequently used teething pow­
der, which contained mercury as calomel 
(Hg2CI2), was removed from the market. Cal­
omel works by poisoning the nerves in the 
baby's gums. When given oraJiy, it is one of 
the less toxic forms of mercury and is about 
100 times less toxic than ethyl mercury to 
neurones in vitro (Deth, 2004). From 1932 to 
1968, 27 tons of organic mercury compounds 
were dumped into Minamata Bay, Japan by 
the Chis o Corporation (Stoller, 2006). Over 
3,000 victims whose normal diet included fish 
from the bay unexpectedly developed symp­
toms of methyl mercury poisoning and have 
been recognized as having Minamata disease, 
a myriad of neurological and neurodevelop­
mental symptoms (Stoller). Mter the out­
breaks in Minamata, congenital Minamata dis­
ease was documented. Pregnant women in 
Minamata who consumed the contaminated 
fish displayed mild or no symptoms but gave 
birth to infants with severe developmental 
disabilities such as cerebral palsy, mental re­
tardation, and seizures. The congenital Mina­
mata disease indicated that the fetal brain may 
be highly sensitive to MeHg exposure (David­
son, Myers, & Weiss, 2004). 
Biochemical and Genomic Basis 
Studies point to the possibility that testoster­
one significantly enhances mercury toxicity, 
whereas estrogen decreases the toxic effects. 
Manning, Baron-Cohen, Wheelwright, and 
Sanders (2001) examined 72 children with 
autism, including 23 children with Asperger 
syndrome, 34 siblings, 88 fathers, 88 mothers, 
and sex and age-matched controls to investi­
gate prenatal testosterone levels in children 
with autistic spectrum disorders (Lutchmaya, 
Baron-Cohen, Raggatt, Knickmeyer, & Man­
ning, 2004; Manning et al.). The authors dem­
onstrated that the more severely autism the 
higher the levels of prenatal testosterone. 
Tordjman, Ferrari, Sulmont, Duyme, and 
Roubertoux (1997) measured plasma testos­
terone and adrenal androgen in nine drug­
free prepubertal children (6-10 years old) 
with autism and 62 neurotypical control chil­
dren of same age, sex, weight (within 2 kg), 
and stage of puberty. Results showed that 
three of the nine children with autism had 
an abnormally high plasma testosterone con­
centration (Tordjman et al.). These studies 
may explain that autism affects males four to 
five times as often as females (Bertrand, Mars, 
et al., 2001; Yeargin-Allsopp et al., 2003). In 
addition, closer observation indicates that the 
more severe the autism the higher the male to 
female ratio. For example, in very severe cases 
males may outntunber females by 15 to 1 or 
even more (Holmes, Blaxill, & Haley, 2003). 
Boris, Goldblatt, Galanko, and James (2004) 
conducted genomic studies of children with 
autism in comparison to normal control pop­
ulations to examine genes in pathways that are 
responsible for the synthesis of key biochem­
ical molecules, which are functionally relevant 
in the excretion and/ or oxidative stress pro­
tection of mercury from the body (Boris et 
al.). Results demonstrated that there was ap­
proximately a twice statistically significant in­
crease in the homozygous methylenetetra­
hydrofolate reductase (MTHFR) 6771T gene 
among children with autism compared to con­
trols. MTHFR 6771T is one of the key genes in 
the biochemical pathway responsible for the 
synthesis of glutathione, a key molecule in the 
body's natural defenses against mercury, and 
those \\ith the MTHFR 6771T gene have been 
found to have an enzyme with only 32% of the 
activity of normal (Chango, Soisson, & Barbe, 
2000).James, Cutler, and Melnyk (2004) eval­
uated the methionine cycle and transsulfura­
tion metabolites in children with autism in 
comparison to age- and sex-matched control 
children Qames, 2004;James et al.). The pro­
cess of cysteine and glutathione synthesis, 
both of which are crucial for natural mercury 
excretion, are reduced in children with autism 
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(Deth, 2004; \\'aly et al.. 2004). Results showed 
that there were significant decreases in the 
plasma concentration of both cysteine ( 19% 
IO\\er) and glutathione (46% lower) in chil­
d1en with autism (James; Jame� et al.). The 
reduCtion of plasma level of C)'Steine and glu­
tathione, among others, adversely affect the 
abilit) to deLOxify and excrete metals like 
mercurv (Deth;James et a1.), which may lead 
to higher Hg concentrations in tissues like 
the nervous S\'Stem and also lead to a longer 
half-life of mercury (Deth; �1utter, :-.:aumann, 
adaghiani, \\'alach, & Drasch. 2005). The 
Emironmental Working Group (EWG) in­
ve�tig:ued the relationship between merctH)' 
exposure, especially mercury exposure from 
thimerosal-<:ontaining childhood vaccines, and 
autistic disorders (Emironmental Working 
Croup, 2004). It is found that there is a severe 
metabolic imbalance in the ratio of active to 
inactive glutathione, the body's most impor­
tant tool for detoxif)ing and excreting metals, 
in children \\ith autism. As a result, these chil­
dren would be susceptible to the harmful ef­
fects of mercun· and other toxic chemical ex­
posures. The E\\'G drew the conclusion that 
by identifving a metabolic common to nearly 
all children with autism that would make these 
children poorly equipped to mount a defense 
against a number of neurotoxic compounds, 
including mercury (Emironmental Working 
Croup). These findings significant]} strengthen 
the possibility that mercurv could cause or 
contribute to autism and other neurodevelop­
mental disorders. These are some of the bier 
chemical and genomic basis for the increased 
bocl)·burden of mercury in children with 
autism. 
Higher Body-Burdens of Mercury 
Several clinical sntdies evaluated the body­
burden of heavy metals prt·sent in children 
with auti�m in comparison to typicall) devel­
oping children (Geier & Geier, 2005b). 
llolmes et al. (2003) and Hu, Bernard, and 
Che (2003) found that despite significantly 
higher mercur:· levels exposure through ma­
ternal dental amalgam and thimerosal con­
taining immunoglobulins during pregnancy 
(Holmes et al.; Hu et a!.), mercury levels in 
the first babies' haircut of 94 children with 
autism were about 8-fold lower than 49 con-
trol children. lnteresringl). Grandjean, Weihe, 
White, and Debes (1998) found that infants 
who reached milestOne criteria early had sig­
nificantly higher merCUI)' concentrations in 
the hair at 12 months of age (Crandjean et al.; 
Mutter, Naumann, Sadaghiani, Schneider, & 
Walach, 2004). It was also observed that the 
more severe the autism the lower mercury 
levels were present in the fi.r'St baby haircut, 
which leads to the conclusion that the mer­
cur:· levels in the first baby haircuts were in­
verselv related to the se\erit) of the autism 
(Geier & Geier). Further studies showed ele­
vated le\·els of mercury, lead and uranium in 
haircuts from 40 older children witl1 autism 
in comparison to 40 normal controls, while 
there was no difference for other toxic metals 
like aluminium, arsenic, cadmium or beryl­
lium (Fido & AI-Saad, 2005). Bradstreet et al. 
evaluated the concentration of heavy metals in 
the urine among 221 vaccinated children with 
autistic spectrum disorders in comparison to a 
neurot)·pical control population (Bradstreet, 
Geier, & Karvinel, 2003). Based on excretion 
following an identical three-da� oral provoca­
tion \�ith 1�0 2,3-dimercaptosuccinic acid 
(DMSA), there were approximately six times 
significantly greater urinary mercury concen­
trations among vaccinated children with au­
tism matched to vaccinated neurotyptical con· 
trois, whereas the two groups of children had 
similar urinary cadmium and lead concen­
trations. Following DMSA treatment, similar 
urinary mercurv concentration levels were o� 
sen·ed among matched vaccinated and um'<lc­
cinated neurotypical children. Results suggest 
that after exposure to mercury, children with 
autism are unable to properly eliminate mer­
cury and thus have significantly higher body­
burdens of mercury than neurotypical chil­
dren (Brddstreet et al.). 
Slikker from the FDA confirmed that thi­
merosal crm.,es the bloodbrain barrier and 
placental barriers. resulting in appreciable 
merCul) content in u�ues including the brain 
(Siikker, 2000). In addition, Sager reported 
the half-life of mercury in the brain of infant 
primates was approximately 28 days follow­
ing administration of solutions containing vac­
cine comparable concentrations of thimerosal 
(Institute of Medicine, 2004). 
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Mercury Exposure during Pregnancy 
Even before they are born, it is speculated that 
children with autism may have had a higher 
mercury exposure during pregnancy due to ma­
ternal dental amalgam, thimerosal-containing 
immunoglobulin shots, and fish consumption. 
Vahter et al. (2000) examined the different 
species of mercury in the blood of pregnant 
women. They found high correlations between 
inorganic mercury levels in blood and urine 
during early pregnancy, a significant correla­
tion between cord and maternal blood, and 
decreased mercury levels during lactation, 
presumably due to excretion in milk (Vahter 
et al.). 
Dental amalgam consists of about 50% of the 
most toxic nonradioactive element (Mutter, 
Naumann, Walach, & Daschner, 2005), and 
of other heavy metals as tin, copper, silver, 
zinc additionally. Amalgam fillings were first 
used in 1830 in the United States (Stoller, 
2006). By 1840, organized dentistry denounced 
the use of amalgam as a poor filling material 
because of concerns about mercury poison­
ing, and the American Society of Dental Sur­
geons was formed and required members to 
sign a pledge promising not to use mercury 
fillings. In 1926, Dr. Alfred Stock, a chemist, 
noted that mercury amalgam fillings in the 
mouth were a source of mercury vapor 
(Stoller). Mercury vapor escapes during the 
preparation and placement of amalgam resto­
rations. Some of the vapor may be inhaled 
(Davidson et al., 2004). Research indicates 
that mercury levels in human placentas corre­
late with the number of maternal amalgam 
fillings and a substantial amount of mercury 
from amalgam reaches the fetus (Stoiber et al. 
2004; Their et al., 2003). 
Rh-negative women were routinely given 
Rhogam injections several times during their 
pregnancies until recently. Those Rhogam in­
jections contained significant amounts of thi­
merosal, which has been removed only re­
cently (Geier & Geier, 2003). Additionally, 
there are other prescription drugs and over­
the,ounter medications that contain signifi­
cant amounts of thimerosal (Geier & Geier). 
As Davidson et al. (2004) pointed out, the 
principal source of organic mercury that hu­
mans are exposed to in the aquatic environ­
ment is atmospheric mercury deposited on 
the surfaces of bodies of water that is then 
biomethylated by microorganisms and subse­
quently biomagnifies as it ascends the food 
chain. Some older, larger carnivorous fish at 
the top of the food chain can contain more 
than 1 ppm. Infants and children may be ex­
posed postnatally to mercury from breast milk 
if their mother consumes foods that contain 
high levels or if they consume fish or foodstaff 
that contain fish products (Davidson et al.). 
The FDA currently recommends that preg­
nant women and those women who may be­
come pregnant avoid species with the highest 
average amounts of methylmercury and that a 
balanced diet of seafood consumption should 
be followed to keep methylmercury levels low 
(Geier & Geier, 2003). 
Mercury Exposure after Birth 
The regressive form of autism is rising at a 
much higher rate than the form of autism 
evident from birth. The regressive form now is 
felt to make up close to 75% of the new cases 
Qepson, 2004). Jepson uses the rise in envi­
ronmental exposure to explain that more 
children nowadays have less severe deficits 
genetically. 
Elemental mercury is the form of mercury 
represented in the hazardous air pollutant 
(HAP) database (Windham, Zhang, Gunier, 
Croen, & Grether, 2006). Every year, there are 
approximately 3,400 metric tons of elemental 
mercury released into the environment, 95% 
among which resides in terrestrial soils, 3% in 
ocean surface waters, and the remaining 2% 
in the atmosphere. Approximately 70% of the 
mercury in the environment comes from an­
thropogenic sources such as coal-fired electric 
power generation facilities and industrial 
waste. Natural sources, however, also deposits 
it in the environment from volcanos, mines, 
and the erosion of ores (Davidson et al., 
2004). 
Windham eta!. (2006) linked the California 
autism surveillance system to estimated haz­
ardous air pollutant (HAP) concentrations 
compiled by the U.S. Environmental Protec­
tion Agency (EPA) to explore possible associ­
ations between autism spectrum disorders 
(ASD) and environmental exposures. They in­
cluded 284 children with ASD and 657 con­
trols, born in 1994 in the San Francisco Bay 
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area. Results suggest a potential assoc1auon 
between autism and estimated metal concen­
trations (Windham et al.). Palmer, Blanchard, 
Stein, Mandell, and Miller (2006) did an epi­
demiologic study, linking Toxic Release In­
ventory (TRJ) data on mercury to special ed­
ucation data in Texas. The study reponed a 
61% increase in autism prevalence rates (or 
17% adjusted) per 1,000 pounds of mercury 
released (Palmer et al.). 
Thimerosal is an ethylmercury-containing 
compound (49.6% mercury by weight) (Geier 
& Geier, 2006). It is a presetvative that is 
added to many vaccines at 0.005% to 0.01% 
level to prevent bacterial contamination and 
thus, prolonging shelf-life and facilitating multi­
use vials. It has become a major source of 
mercury among children in the United States 
since within their first two years of life, who 
may have received a quantity of mercury that 
exceeded Federal Safety Guidelines (Ball, Ball, 
& Pratt, 2001; Redwood, Bernard, & Brown, 
2001). Geier and Geier pointed out that the 
routine childhood immunization schedule used 
to include five doses of Thimerosal-containing 
Diptheria-Tetanus-whole-cell-Pertussis (DTP) vac­
cine with the first dose being administered at 
two months of age. From the late 1980s through 
the 1990s, the Centers for Disease Control and 
Prevention (CDC) expanded the number of 
doses of Thimerosal-containing vaccines to be 
administered to US infants. Eventually, the 
immunization schedule came to be composed 
of three doses of Thimerosal-containing hep­
atitis B vaccine with the first dose adminis­
tered as early as the day of birth, and four 
doses of Thimerosal-containing Haemophilus 
Influenzae type b (Hib) vaccine with the first 
dose administered at two months of age. Ad­
ditionally, the CDC also began recommended 
that three doses of Thimerosal-containing in­
fluenza vaccine be administered to certain in­
fant population with the first dose adminis­
tered by the sixth month of age (Geier & Geier). 
As a result, if all thimerosal-containing vac­
cines were administered according to the im­
munization schedule recommended by the 
CDC, infants in the United States may have 
been exposed to 12.5 micrograms (J.tg) of eth­
ylmercury at birth, 62.5 p.g at two months, 
50 p.g at four months, 62.5 p.g at six months, 
and 50 J.tg at 18 months, for a total of 237.5p.g 
of ethylmercury during the first 18 months of 
life (Ball et al., 2001; Redwood et al., 2001). In 
addition, if three thimerosal-containing influ­
enza vaccines were administered during the 
first 18 months of life as they were suggested 
to certain infant population, the total mercury 
exposure could have been as high as 275 p.g of 
mercury (Ball et al.; Redwood et al.). 
Geier and Geier (2004) reviewed the 2003 
US Physician's Desk Reference (POR) and 
found that some childhood \'accines still con­
tain thimerosal. For example, DTaP manufac­
tured by Aventis Pasteur contains 25 p.g of 
mercury, b (Hib) vaccine manufactured by 
Wyeth contains 25 p.g of mercury, and pediat­
ric hepatitis B vaccine manufactured by Merck 
contains 12.5 p.g of mercury. Additionally, in­
fluenza vaccine recommended for an increas­
ing population also contains 25 J.tg of mercury. 
Therefore, possible total childhood mercury 
in the United States in 2003 is more than 
300 p.g, among which levels of mercury from 
thimerosal contained childhood vaccinations 
are higher than at any time in the past (Geier 
& Geier). Furthermore, injecting thimerosal 
into infants muscle also bypasses the GI tract, 
one of the body's first-line defense mecha­
nisms (Geier & Geier). 
In 1982, an expert panel at the Food and 
Drug Administration (FDA) reviewed thimer­
osal, reponed it as toxic, causing cell damage, 
ineffective in killing bacteria or halting their 
replication, not as safe or effective as gener­
ally recognized (Federal Register, 1982), and 
thus called for it� •·emO\-al in over-the-counter 
product5 (Stoller, 2006). In 1988, the FDA 
ruled that thimerosal should be removed from 
OTC products, but gave the industry another 
16 years to phase out its presence. In 1999, 
the FDA announced that under the recom­
mended childhood immunization schedule, 
infants might be exposed to cumulative doses 
of ethylmercury from \<ICcines that exceed 
federal safety guidelines established for the 
oral ingestion of methylmercury (Geier & 
Geier, 2006). In the same year of 1999, the 
Public Health Service (PHS) and the Ameri­
can Academy of Pediatrics (AAP) issued a 
joint statement calling for the removal of 
thimerosal from all childhood vaccines as 
soon as possible due to any potential 1isk 
(Stoller). In 2001, the FDA required that 
vaccine manufacturers remove thimerosal 
from their \'accines. In the same year of 2001, 
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the Institute of Medicine (IOM) stated that it 
was biologically plausible for mercury from 
thimerosal-<:ontaining childhood vaccines to 
cause childhood neurodevelopmental disor­
ders (Geier & Geier, 2004). Interestingly, 
thimerosal was taken out of animal vaccines a 
decade ago because of the safety concern 
(Stoller). 
The Environmental Protection Agency 
(EPA) 's safety guideline of vicinal thimerosal 
is 1 part-per-million (ppm) for one-year old. 
Redwood et al. (2001) utilized a one compart­
ment pharmacokinetic model to estimate 
hair mercury concentrations expected to re­
sult from the recommended CDC childhood 
immunization schedule during the 1990s, and 
the results indicated that modeled hair mer­
cury concentrations in infants exposed to vici­
nal thimerosal were in excess of the EPA's 
safety guidelines for up to the first 365 days, 
with several peak concentrations within this 
period (Geier & Geier, 2005b; Redwood et 
al.). Nowadays in the United States, thimero­
sal has been removed from many vaccines 
administered to infants, but there is no recall 
of the existing thimerosal-<:ontaining product. 
Additionally, other thimerosal-<:ontaining 
vaccines are still being developed and mar­
keted such as influenza, Tetanus-diphtheria, 
Rhogam, and monovalent tetanus. Thimero­
sal has also been present in other commercial 
products such as contact lens solution, which 
was removed in 1998, eardrops and various 
nasal preparations Uepson, 2004). 
Thimerosal has been recognized as a devel­
opmental toxin by the California Environ­
mental Protection Agency, Office of Environ­
mental Health Hazard Assessment. Maternal 
exposure during pregnancy can disrupt the 
development, cause birth defects, low birth 
weight, biological dysfunctions, or even the 
death of the fetus, and exposure to it can also 
cause psychological or behavior deficits that 
become evident as the child grows (Geier & 
Geier, 2005). In vitro, mercury and thimerosal 
in levels reached eight days after vaccination 
inhibit methionine synthetase (MS) by 50%. 
MS is crucial in biochemical steps for brain 
development, attention, and production of 
glutathione, an important antioxidative and 
detoxifying agent. Subsequendy, children with 
autism have significantly decreased level of 
reduced glutathione (Geier & Geier). ln ad-
dition, a study reported that thimerosal was a 
potent inhibitor of phagocytosis, which is the 
first step of the innate immune system (Ram­
persad et al., 2005). While the acquired in­
nate immune system can be only built up by 
aging, it seems likely that injection of thimer­
osal would inhibit an infant's immune system. 
Fagan, Pritchard, Clarkson, and Greenwood 
( 1977) reported that 10 children out of 13 
treated with a thimerosal containing topolog­
ical "antiseptic" for umbilical cord infection 
died, even though this antiseptic was used 
world-wide on adolescents and adults and very 
little negative effects were reported. This 
strongly implied that infants were much more 
susceptible to thimerosal toxicity than others 
(Mutter, Naumann, Schneider, et al., 2005). 
An ecological study evaluated birth cohorts 
from the mid-1980s through the late 1990s to 
investigate the relationship between the aver­
age mercury doses children received from 
thimerosal-<:ontaining vaccines in comparison 
to the prevalence of autism. Results showed 
that there was an increasing linear correlation 
between the amount of mercury children re­
ceived from thimerosal-<:ontaining vaccines 
and the cohort prevalence of autism (Geier & 
Geier, 2004). 
Epidemiological studies conducted in the 
United States using various databases, includ­
ing the California Department of Develop­
mental Services (CDDS), Vaccine Adverse 
Event Reporting System (VAERS), US Depart­
ment of Education, and the Vaccine Safety 
Datalink (VSD) to examine the relationship 
between th.imerosal-<:ontaining childhood vac­
cines and neurodevelopmental disorders (Geier 
& Geier, 2006). Results indicate significant links 
between exposure to Thimerosal-<:ontaining 
vaccines and neurodevelopmental disorders, 
showing that in comparison to children re­
ceiving thimerosal-free childhood vaccines, 
children receiving thimerosal-<:ontaining child­
hood vaccines were two- to six-fold statistically 
significantly increased risks to develop neuro­
developmental disorders, depending upon the 
specific conditions or symptoms examined 
(Geier & Geier, 2005b). 
Geier and Geier (2003) evaluated doses of 
mercury from thimerosal-<:ontaining child­
hood immunizations in comparison to U.S. 
Federal Safety Guidelines. Results showed that 
children received mercury from thimerosal-
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containing vaccines, as part of the routine US 
childhood immunization schedule, in excess 
of the Federal Safety Guidelines for the oral 
ingestion of methylmercury. Secondly, based 
upon the Vaccine Adverse Events Reporting 
System (VAERS) database, Geier and Geier 
investigated the effects of increasing doses of 
mercury on the incidence rates of neuro­
development disorders reported following 
thimerosal-containing vaccines in comparison 
to thimerosal-free vaccines. Outcomes showed 
increasing relative risk of neurodevelopment 
disorders v.<ith increasing doses of mercury. 
Finally, the authors used data from the US 
Department of Education to analyze the prev­
alence of school children at various ages with 
various types of disabilities in comparison to 
the mercury dose that children received from 
thimerosal in their childhood vaccines. The 
analyses showed autism and speech disorders 
were correlated with increasing mercury from 
childhood vaccines (Geier & Geier). 
Geier and Geier (2004) used the Biological 
Surveillance Summaries of the Centers for 
Disease Control and Prevention (CDC), the 
U.S. Department of Education datasets, and 
the CDC's yearly live birth estimates to evalu­
ate the effects of mercury from thimerosal­
containing childhood vaccines on the preva­
lence of autism. Results indicated that there was 
a close correlation between mercury doses from 
thimerosal-containing childhood vaccines and 
the prevalence of autism from the mid-to-late 
1980s through the mid-1990s. Additionally, it 
was found that there were statistically signifi­
cant odds ratios for the prevalence of autism 
following increasing doses of mercury from 
thimerosal-containing vaccines with birth co­
horts of 1985 and from 1990 to 1995 in com­
pa•ison to a baseline measurement with birth 
cohort of 1984 (Geier & Geier). 
Geier and Geier (2005) did a two-phased 
population-based epidemiological study. Phase 
one examined reported neurodevelopmental 
disorders (NDs) to the Vaccine Adverse Event 
Reporting System (V AERS) following thimer­
osal-containing Diphtheria-Tetanus-acellular­
Pertussis (DTaP) vaccines in comparison to 
thimerosal-free DTaP vaccines administered 
from 1997 through 2001. Phase two evaluated 
the automated Vaccine Safety Datalink (VSD) 
for cumulative exposures to mercury from 
thimerosal-containing vaccines at 1-, 2-, 3-, and 
6-months of age for infants born from 1992 
through 1997 and the eventual risk of devel­
oping NOs to determine whether the affect 
from thimerosal-containing childhood vaccines 
on neurodevelopmental disorders observed 
in the VSD database was consistent with ob­
servations made in the VAERS database. Re­
sults showed that exposure to mercury from 
thimerosal-containing childhood vaccines ad­
ministered in the United States was a consis­
tent significant risk factor for the develop­
ment of Ds (Geier & Geier). 
Geier and Geier (2006) also conducted a 
meta-analysis epidemiological assessment of 
the Vaccine Adverse Event Reporting Sys­
tem (VAERS) for neurodevelopment disor­
ders (NOs) reported following Diphtheria­
Tetanus-whole-cell-Pertussis (DTP) vaccines 
in comparison to Diphtheria-Tetanus-whole­
cell-Pertussis-Haemophilus lnfluenzae Type b 
(DTPH) vaccines administered from 1994 to 
1997 and following Thimerosal-containing 
Diphtheria-Tetanus-acellular-Pertussis ( DTaP) 
vaccines in comparison to Thimerosal-free 
DTaP vaccines administered from 1997 to 
2000. Results demonstrated that a significant 
risk factor for the development of neurodevel­
opmental disorders was the amount of mer­
cury children received from Thimerosal­
containing childhood immunizations, thus 
there is a significant relationship between the 
Thimerosal-containing childhood vaccines 
evaluated and childhood neurodevelopmen­
tal disorders (Geier & Geier). 
Conclusion 
To sum up, there has been a great deal of 
information from different studies that seems 
to indicate that repetitive mercury exposure 
during pregnancy, through thimerosal, dental 
amalgam, and fish consumption, and after 
birth, through thimerosal-containing vaccina­
tions and pollution, in genetically susceptible 
individuals is one potential factor in autism. 
Certainly this question continues to stir de­
bate among professionals across the medical 
and behavioral sciences. It serves as a grey area 
for many families as they seek to quell their 
anxiety invoked by this debate by discovering 
the facts. The purpose of this article was to 
synthesize the findings relative to this ques­
tion to hopefully sen;e as a resource to educa-
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tors as we seek lO become more well-informed 
on this timely issue. As the prevalence rate for 
allli m in children continues to rise. more 
research is n eeded to better understand 
causal factors. It is also crucial that quality 
re,iews be conducted to synthesize a body of 
knowledge pertaining to these questions if the 
puule is to be solved pertaining to the link 
between mercury exposure and autism. 
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